Form 144 EyePoint For: 21 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eyepoint Pharmaceuticals Inc (EYPT)
Track the Eyepoint Pharma share price today and view real-time EYPT share price data, including charts, technicals, and key financials. View the EYPT premarket stock price ahead of the market session or assess the after hours quote. Explore EYPT stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Eyepoint Pharma Stock Price Today?
The Eyepoint Pharma stock price today is 12.190.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is ""EYPT.""
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharma a Good Stock to Buy?
Determining whether Eyepoint Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
What Is the Eyepoint Pharma Stock Price Today?
The Eyepoint Pharma stock price today is 12.190.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is ""EYPT.""
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharma a Good Stock to Buy?
Determining whether Eyepoint Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.060
12.498
52 wk Range
9.400
19.110
Earnings results expected in 10 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.06012.498
52 wk Range
9.40019.110
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EYPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
40.286
Upside
+230.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
pSivida Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 144 EyePoint For: 21 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 40.286
(+230.48% Upside)
Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- EyePoint missed Q1 2026 forecasts with EPS of -$0.99 vs. -$0.82 expected; revenue fell 97.1% YoY to $0.7M as deferred revenue recognition ended.
- Operating expenses rose 20.5% to $88M driven by Phase III trials for DURAVYU; net loss widened to $85M from $45M in Q1 2025.
- Company maintains $223M cash position expected to fund operations through Q4 2027 without additional financing needs.
- DURAVYU Phase III wet AMD data expected mid-2026; DME trial enrollment to complete Q3 2026 as company pursues first-in-class treatment status.
- Stock rose 2.28% to $14.064 despite earnings miss, reflecting investor optimism about clinical pipeline despite high cash burn and regulatory risks.
Last Updated: 06/05/2026, 11:52 pm
Read Full TranscriptEarnings
Latest Release
06/05/2026
EPS / Forecast
-0.99 / -0.82
Revenue / Forecast
696K / 1.01M
Compare EYPT to Peers and Sector
Metrics to compare | EYPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEYPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −3.5x | −0.3x | |
PEG Ratio | 0.08 | −0.18 | 0.00 | |
Price/Book | 4.4x | 1.1x | 2.6x | |
Price / LTM Sales | 134.2x | 2.0x | 2.9x | |
Upside (Analyst Target) | 199.4% | 63.6% | 57.8% | |
Fair Value Upside | Unlock | 51.3% | 9.5% | Unlock |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Eyepoint Pharma (EYPT) Stock Price Today?
The Eyepoint Pharma stock price today is 12.190 USD.
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is "EYPT."
What Is the Eyepoint Pharma Market Cap?
As of today, Eyepoint Pharma market cap is 1.020B USD.
What Is Eyepoint Pharma's Earnings Per Share (TTM)?
The Eyepoint Pharma EPS (TTM) is -3.513.
When Is the Next Eyepoint Pharma Earnings Date?
Eyepoint Pharma will release its next earnings report on 05/08/2026.
From a Technical Analysis Perspective, Is EYPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Eyepoint Pharma Stock Split?
Eyepoint Pharma has split 2 times.
How Many Employees Does Eyepoint Pharma Have?
Eyepoint Pharma has 214 employees.
What is the current trading status of Eyepoint Pharma (EYPT)?
As of 26/07/2026, Eyepoint Pharma (EYPT) is trading at a price of 12.190 USD, with a previous close of 12.470 USD. The stock has fluctuated within a day range of 12.060 USD to 12.498 USD, while its 52-week range spans from 9.400 USD to 19.110 USD.
What Is Eyepoint Pharma (EYPT) Price Target According to Analysts?
The average 12-month price target for Eyepoint Pharma is 40.286 USD, with a high estimate of 68 USD and a low estimate of 20 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +230.48% Upside potential.
What Is the EYPT Premarket Price?
EYPT's last pre-market stock price is 12.710 USD. The pre-market share volume is 20.000, and the stock has decreased by 0.240, or 1.920%.
What Is the EYPT After Hours Price?
EYPT's last after hours stock price is 12.500 USD, the stock has decreased by 0.310, or 2.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.